ArticleBone marrow transplantation2026
Impact of anti-T-lymphocyte globulin dosing on graft versus host disease in matched sibling peripheral blood stem cell transplantation.
Article in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Blood cell-derived transplants at 40.Bone marrow transplantation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-T-lymphocyte globulin (ATLG) is commonly administered to reduce graft-versus-host disease (GVHD) in allogeneic stem cell transplantation (allo-SCT). However, the optimal ATLG dose in matched-sibling-donor (MSD) peripheral blood stem-cell transplantation (PBSCT) remains uncertain. We compared two ATLG doses (15 mg/kg vs. 30 mg/kg) in the MSD-PBSCT setting to assess allo-SCT outcomes. In this single-center retrospective study, we included 165 consecutive patients with hematologic malignancies who underwent MSD-PBSCT. Of these, 71 received 15 mg/kg ATLG (ATLG-15), and 94 received 30 mg/kg ATLG (ATLG-30). ATLG-15 was associated with earlier leukocyte (median 11 vs. 12 days, p = 0.004) and platelet engraftment (median 12 vs. 15 days, p = 0.0002). Moderate/severe chronic GVHD at 2 years was significantly higher with ATLG-15 (43% vs. 28%, p = 0.045), with no difference in OS, PFS, NRM, or CIR. In multivariable analysis, ATLG-30 was associated with improved GRFS (HR 0.47, p = 0.02). After propensity score matching, GRFS and all-grade cGVHD remained significantly better with ATLG-30 (p = 0.047), with a trend toward reduced moderate/severe cGVHD (p = 0.067). In AML/MDS patients not receiving TBI (n = 108), moderate/severe cGVHD remained lower with ATLG-30 (19% vs. 38%, p = 0.039). Our study suggests that ATLG-30 in MSD-PBSCT reduces moderate/severe cGVHD and improves GRFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.